


SUPPLEMENTAL MATERIAL:


Supplemental Table S1. Antibody and reagent information.

Reagents Name	company	Catalog #	Clone #	Lot #	Expire
Anti-h CD45-BUV395	BD	563792	HI30	9269807	
BD Pharm Lyse™ lysing solution	BD	555899		8149712	
Anti-h CD4-BV510	Biolegend	317444	OKT4	B292551	
Anti-h CD8a-PE-Cy5	Biolegend	300910	HIT8a	B300799	
Anti-h CD14-Alexa 700	Biolegend	325614	HCD14	B243612	
Anti-h CD3-APC-Cy7	Biolegend	317342	OKT3	B282905	
Anti-h CD274-PE	Biolegend	329706	29E.2A3	B272166	
Mouse isotype PerCP/Cy5.5	Biolegend	400338	MPC-11	B275227	
Mouse isotype PE	Biolegend	402204	27-35	B271045	
Mouse isotype APC	Biolegend	402206	27-35	B272605	
Anti-h CD86-APC	Biolegend	374208	BU63	B262802	
Anti-h CTLA4-PerCP/Cy5.5	Biolegend	369608	BNI3	B267053	
Anti-h CD107α-PE	Biolegend	328608	H4A3	B283846	
Anti-h CD160-PerCP/Cy5.5	Biolegend	341210	BY55	B262314	
Anti-h CD223-PE(LAG-3)	Biolegend	369206	7H2C65	B271246	
Anti-h CD25-APC	Biolegend	302610	BC96	B258747	
Anti-h CD80-FITC	Biolegend	305206	2D10	B219028	
Anti-h CD279-PerCP/Cy5.5 (PD1)	Biolegend	329914	EH12.2H7	B267952	
Zombie UV dye	Biolegend	423108			
Anti-h CEA-Alexa 488	R&D Systems	FAB41281G	487609	1536943	
Human XL Cytokine Luminex Performance Assay Fixed Panel	R&D Systems	LKTM014		P189369	
Pooled normal human male AB Serum	Innovative Research	IPLA-SERAB-27146			Jul2023
Anti-human EPCAM:	Ventana	760-4383	1Ber-EP4	V0002926	
Anti-human PD-L1	Ventana	740-4907	SP263	F31218	
Anti-human Foxp3	abcam	ab20034	236A/E7	GR3409148-8	
Anti-FLAG Tag (DYKDDDDK)	Cell Signaling	14793	D6W5B	No.4	
Paraformaldehyde 32%	Electron Microscopy Sciences	15714		181210-10	



Supplemental Figure S1. CD8+ and CD4+ T cell immune marker expression of ex vivo cells from patients with GCPM. Fresh ex vivo cells from peritoneal washing (PW(-)) or malignant ascites (MA) were stained with anti-CD45, anti-CD3, anti-CD4, and anti-CD8 antibodies and the markers shown in the figure. CD8+ T cells (A) and CD4+ T cells (B) were gated and analyzed as a histogram for immune markers. One representative of each marker is shown in the figure.

Previous treatment (PT) vs no previous treatment (NPT)



Supplemental Figure S2. Evaluation of previous treatment versus no previous treatment for the efficacy of virus-killing ex vivo cancer cells at the 15 hour time point. A total of 12 samples, of which there were 9 samples with previous treatment (PT) and 3 samples with no previous treatment (NPT) before specimen collection, were treated with PBS, CF33-GFP (MOI=3), or CF33-hNIS-antiPDL1 (MOI=3) for 15 hours and the dead cell percentage of each group is shown in the figure (Mean±SEM).